The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial.
Saved in:
| Title: | The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. |
|---|---|
| Authors: | Ruan DY; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Wu HX; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Luo SX; Phase I Clinical Research Center, Henan Cancer Hospital, Zhengzhou, China., Huang WW; Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China.; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China., Liang XJ; Department of Abdominal Oncology, Hubei Cancer Hospital, Wuhan, China., Niu ZX; Department of Medical Oncology, Cancer Hospital of Shandong First Medical University, Ji'nan, China., Dang Q; Phase I Clinical Research Center, Cancer Hospital of Shandong First Medical University, Ji'nan, China., Li HL; Department of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Pan ZY; Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., Lu HX; Department of Gastroenterology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China., Zhang YQ; Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China., Li XY; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China., Xiao XY; Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Cai SR; Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Dong YG; Phase I Clinical Trial Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China., Zhang J; Department of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China., Li Z; Department of General Surgery, ZhuJiang Hospital of Southern Medical University, Guangzhou, China., Lan HT; Department of Medical Oncology, Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital, Chengdu, China., Wang X; Department of Gastrointestinal Surgery, Peking University First Hospital, Beijing, China., Zhou Y; Department of Pharmacy & Drug Clinical Trial Institution, Peking University First Hospital, Beijing, China., Liu L; Department of Medical Oncology, Qilu Hospital of Shandong University, Ji'nan, China., Liu HL; Department of Gastrointestinal Surgery, Xiangya Hospital Central South University, Changsha, China., Xu PS; Phase I Clinical Trial Research Center, Xiangya Hospital Central South University, Changsha, China., Suo AL; Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China., Jia RN; Department of Digestive Oncology, The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, China., Li YQ; Department of Digestive Oncology, Cancer Hospital Affiliated to Guangxi Medical University, Nanning, China., Peng XD; Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China., Wang SC; Department of Clinical Pharmacology, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China., Yu AA; Department of Biometrics, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China., Xie J; Oncology Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China., Qiu MZ; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. qiumzh@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China. qiumzh@sysucc.org.cn., Xu RH; Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China. xurh@sysucc.org.cn.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Guangzhou, China. xurh@sysucc.org.cn. |
| Source: | Nature medicine [Nat Med] 2025 Sep; Vol. 31 (9), pp. 3037-3046. Date of Electronic Publication: 2025 Jul 16. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
